Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $12.4 million.

  • Heron Therapeutics' Short-term Investments fell 7249.33% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 7249.33%. This contributed to the annual value of $33.5 million for FY2024, which is 3527.99% down from last year.
  • Per Heron Therapeutics' latest filing, its Short-term Investments stood at $12.4 million for Q3 2025, which was down 7249.33% from $24.1 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Short-term Investments peaked at $106.7 million during Q1 2021, and registered a low of $12.4 million during Q3 2025.
  • Over the past 5 years, Heron Therapeutics' median Short-term Investments value was $45.1 million (recorded in 2024), while the average stood at $47.8 million.
  • As far as peak fluctuations go, Heron Therapeutics' Short-term Investments tumbled by 7346.71% in 2021, and later skyrocketed by 14750.28% in 2024.
  • Quarter analysis of 5 years shows Heron Therapeutics' Short-term Investments stood at $67.0 million in 2021, then grew by 3.65% to $69.5 million in 2022, then dropped by 25.55% to $51.7 million in 2023, then tumbled by 35.28% to $33.5 million in 2024, then crashed by 62.91% to $12.4 million in 2025.
  • Its Short-term Investments was $12.4 million in Q3 2025, compared to $24.1 million in Q2 2025 and $31.4 million in Q1 2025.